Evidence map›Paper›PMID 17453286›Full record

ReviewWorld journal of surgery2007

Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Andreas Machens, Henning Dralle

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Thyroid : official journal of the American Thyroid Association · 2015
    Guideline
  2. Gland surgery · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. RET mutations in a large indian family with medullary thyroid carcinoma.Indian journal of endocrinology and metabolism · 2014
    Article
  9. Article
  10. An unusual presentation of MEN2A.BMJ case reports · 2013
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. [Surgery of thyroid carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2009
    Article
  17. Review
  18. [Hereditary thyroid cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2008
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andreas MachensDepartment of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06097, Halle/Saale, Germany. AndreasMachens@aol.com
Henning Dralle
Martin Luther University Halle-Wittenberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince DNA tests have enabled reliable identification of asymptomatic RET (rearranged during transfection) gene carriers, myriads of publications have appeared on genotype-phenotype relationships. A comprehensive appraisal of this body of evidence using evidence-based methodology is pending.

methodsThis study was based on systematic evaluation of the literature using evidence-based criteria.

results(1) There is a distinct age-related progression of hereditary medullary thyroid carcinoma (MTC) in carriers of RET mutations (grade C). (2) Among the high-risk RET mutations, those in codon 634 cause higher penetrance rates of the multiple endocrine neoplasia 2A phenotype (MTC, pheochromocytoma, and parathyroid hyperplasia/adenoma) than mutations in codons 609, 611, 618, and 620, irrespective of the amino acid substituting for cysteine (grade C). (3) DNA-based screening is superior to calcitonin-based screening in asymptomatic RET carriers (grade C). (4) Using a worst-case scenario, i.e., considering the earliest finding of MTC in asymptomatic RET carriers, pre-emptive thyroidectomy should be performed before that time (grade C) to be truly prophylactic. Specifically, for carriers of highest-risk mutations (codon 918): within the first year of life; for carriers of high-risk mutations (codon 609, 611, 618, 620, 630, and 634): before the age of 5 years; and for carriers of least-high risk mutations (codon 768, 790, 791, 804, and 891): before the age of 5-10 years. Strict adherence to these grade C recommendations can result in undertreatment of the former (codon 634) and overtreatment of the latter.

conclusionsThese genotype-phenotype correlations provide a solid foundation on which to base surgical concepts, leaving little room for randomized controlled clinical trials.

Indexed as

Age FactorsCarcinoma, MedullaryCodonDisease ProgressionEvidence-Based MedicineGenetic Predisposition to DiseaseGenotypeHumansMultiple Endocrine Neoplasia Type 2aMutationPenetrancePhenotypeProto-Oncogene Proteins c-retThyroidectomyThyroid NeoplasmsCodonProto-Oncogene Proteins c-retRET protein, human

Identifiers

PMID17453286
OpenAlexW2006088200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.